– GERMANY, Munich – LEUKOCARE, a leading provider of stabilizing and protecting formulation technologies for proteins and other biologics, today announced the closing of its latest financing round providing growth capital to the company. The round was led by LifeCare Partners, a dedicated venture capital and private equity firm in the European healthcare sector, with participation from a group of new investors and current shareholders.
The financing will primarily be used to fund market access activities for a number of development projects based on LEUKOCARE’s Stabilizing and Protecting Solutions (SPS®) in the fields of vaccines, biopharmaceuticals and combination devices.
“We believe that LEUKOCARE’s SPS® formulation technology platform has the potential to bring a complete paradigm shift in improving thermal stability and shelf life of biological products and vaccines“, says Dr. Gerhard Ries, Managing Partner at LifeCare Partners. “Unlike other formulation approaches, the SPS® technology facilitates a quantum leap in stabilizing biological molecules by offering even outstanding protection during sterilization of biopharmaceuticals and bio-functionalization of medical devices as well as avoiding cold chain logistics for vaccines”.
As part of the financing, Dr. Gerhard Ries and Dr. Jean-Paul Prieels will join the supervisory board. Dr. Jean-Paul Prieels is a renowned industry expert in the vaccine field. He held various executive positions at GlaxoSmithKline, where he headed the vaccine research and development. “LEUKOCARE has developed an outstanding technology platform to develop exceptionally 2 stable formulations for all kinds of biologics and particularly for vaccines”, says Dr. Prieels. “I am deeply impressed by the potential of the SPS® technology platform and looking forward to support its further development as well as its roll out based on my network and my expertise in the field of vaccines.”
”I am very proud to welcome the new investors as well as the new board members,” states Michael Scholl, CEO with LEUKOCARE. “The fact that dedicated industry experts decided to support LEUKOCARE both with capital as well as substantial input is a validation of the path that we are successfully pursuing. It is a further essential step to assure our position as a reliable and competent provider of innovative formulation technologies to the industries of biopharmaceuticals, vaccines and combination devices.”
About LEUKOCARE AG
LEUKOCARE provides a next-generation formulation technology platform for the protection of proteins like biopharmaceuticals to allow the development of better products. The proprietary Stabilizing and Protecting Solutions (SPS®) technologies are provided to development projects of partners in the pharmaceutical and medical device industry. LEUKOCARE’s SPS® technologies improve stability and quality of biologics like antibodies, vaccines etc. in dry and liquid formulation and protect proteins in biologically functionalized combination devices.
LEUKOCARE is a privately owned biotechnology company founded in 2003, and headquartered in Martinsried/Munich, Germany. LEUKOCARE is currently involved in more than 15 collaborations with industrial partners.
About LifeCare Partners
LifeCare Partners is an independent investment firm providing financing to private and public life science companies. LifeCare Partners targets the entire life science industry with special focus on medical technology, diagnostics, biopharmaceuticals, food & nutrition, industrial biotechnology, biomaterials, e-health and bioenergy. Based in Basel, the LifeCare Partners team has successfully invested in more than 30 life science companies over the last years, of which a large number have already been listed on the stock exchange or have been acquired by leading players in the life science industry.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
